Irisin is an effector molecule in exercise rehabilitation following myocardial infarction (Review)

Shuguang Qin1,2, Zhenjun Tian1\*, Maxime Boidin3,4,5, Benjamin J. R. Buckley6,7,

Dick H. J. Thijssen3,8 and Gregory Y. H. Lip6,7

1. Institute of Sports and Exercise Biology, School of Physical Education, Shaanxi Normal University, Xi'an, Shaanxi, China

2. Department of Cardiology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

3. Liverpool Centre for Cardiovascular Science, Liverpool John Moores University, Liverpool, United Kingdom.

4. Cardiovascular Prevention and Rehabilitation (EPIC) Center, Montreal Heart Institute, Montreal, Canada

5. School of Kinesiology and Exercise Science, Faculty of Medicine, Université de Montréal, Montreal, Canada

6. Liverpool Centre for Cardiovascular Science, University of Liverpool & Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.

7. Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, United Kingdom

8. Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom

**\* Correspondence:**

Professor Zhenjun Tian

tianzhj@snnu.edu.cn

Keywords: irisin, exercise, myocardial infarction, cardiac rehabilitation, cardioprotection.

Abstract

Background

Regular exercise is an effective non-pharmacological therapy for treatment and prevention of cardiovascular diseases (CVD). The therapeutic benefits of exercise are mediated partly through improved vascular and increase in metabolic health. Release of exercise-responsive myokines, including irisin, is associated with beneficial effects of exercise in CVD patients.

Observations

The present review provides an overview of the role of exercise in cardiac rehabilitation of patients with myocardial infarction (MI). Further, the role of irisin as a motion-responsive molecule in improving vascular and metabolic health is explored. Possible mechanism of cardioprotective effect of irisin-mediated exercise on myocardial infarction are also summarized in this review.

Conclusions and significance of the review

Irisin is associated with reduced inflammation, antioxidant properties, and anti-apoptotic effect, implying that it is a potential key mediator of the beneficial effects of exercise on vascular and metabolic health. The findings show that irisin is a promising therapeutic target for treatment of patients with cardiovascular disease, particularly post-MI. Further research should be conducted to elucidate the potential mechanisms of cardioprotective effects of irisin and explored whether irisin induced by exercise exerts rehabilitation effects post-MI.

# Introduction

Exercise is an effective non-pharmacological intervention that improves cardiovascular health and function. Moreover, exercise alleviates cardiovascular disease (CVD) risk factors, and reduces all-cause mortality in CVD patients (1, 2). Due to the dose-response relationship between exercise intensity and/or duration and overall cardiovascular benefit, the correct choice of exercise rehabilitation mode is particularly important for patients with CVD (3, 4). Exercise has been found to improve left ventricular function after myocardial infarction (MI) (5, 6), which beneficial effects are partly mediated by promotion of cardiovascular function, mitochondrial biogenesis, and through stimulation of skeletal muscle to release myokines (7, 8). However, its molecular mechanisms are not clear completely.

Irisin is mainly secreted in skeletal (9) and cardiac muscle tissue (10), and is implicated in modulation of mitochondrial function and energy balance (11, 12) lipid and glucose metabolism (13, 14) , and amelioration of impaired cardiac function in some metabolic disorders (15, 16). Previous findings show that circulating irisin level is lower in patients with chronic heart failure (17), middle cerebral artery occlusion (MCAO) patients (18), and subjects with Alzheimer disease (AD) (19) compared with normal subjects. Low irisin levels are associated with increase in levels of circulating inflammatory cytokines and/or angiotensin Ⅱ observed in various diseases. Exercise is the main inducer of irisin secretion both in healthy and dysregulated metabolism individuals (20). Studies have confirmed that exercise-induced irisin is correlated with improvement of cardiac function in general (21), which partly by modulating autophagy and mitochondrial function (22, 23). Further previous animal studies report that irisin is implicated in cerebrovascular protective effects of exercise by alleviating ischemic neuron injury (18, 24). Irisin has a significant endothelial protective effect (determined by flow-mediated arterial dilation) (25) and inhibits progression of atherosclerosis (determined by flow-mediated arterial dilation (26, 27). These findings indicate that irisin is a potential factor that mediates the protective effects of exercise in patients with cardio-cerebrovascular disease.

In the present review, cardioprotective effect of exercise on MI was explored. Moreover, the role of irisin, as an important exercise effector molecule in cardioprotective effects of exercise training was summarized. In addition, the possible cardiac protective mechanism of irisin reported in clinical studies and animal experiments was reviewed. The findings of the present review indicate that irisin plays an important role in exercise rehabilitation of MI.

# Role of exercise in cardiac rehabilitation of patients with acute myocardial infarction

## Exercise-based cardiac rehabilitation conducted immediately after acute myocardial infarction achieves optimal results

Cardiac rehabilitation is recommended in all patients with ACS, recent myocardial revascularization, stable angina pectoris, and stable coronary artery disease (CAD) (28). Cardiac rehabilitation reduces risk factors, and increases the aerobic fitness, medication adherence, and survival after percutaneous coronary intervention and coronary artery bypass graft surgery (29, 30). Moreover, it improves survival and reduces risk of recurrent MI in patients with acute MI (AMI) (31). A previous meta-analysis comprising 63 trials and 14,486 patients assigned to exercise-based cardiac rehabilitation or no referral following MI or revascularization, reported that cardiac rehabilitation was associated with a lower risk of cardiovascular death (relative risk [RR] 0.74, 95% CI 0.64-0.86) and hospital readmission (RR 0.82, 95% CI 0.70-0.96) at 12-months (32).

The rehabilitation is conducted to play an important role in achieving positive outcomes. Exercise training interventions had significantly higher beneficial effects on left-ventricular remodelling when exercise training is initiated immediately after AMI (from one week). Notably, when exercise was delayed for more than a week, the patients required an additional month of training to achieve the same level of benefit on cardiac remodelling as those who began exercise immediately after AMI (33). A randomised controlled trial (RCT) comprising patients with AMI reported that early training intervention (<2 weeks post-MI) significantly improved health-related quality of life and functional capacity (*through 6-minute walk test*) compared with the control (only usual care) (34). A previous clinical analysis was conducted using regression model to explore the recovery time and health of patients. The results showed that each 1-day increase in cardiac rehabilitation wait time led to a 1% reduction in the likelihood of improvement across all fitness-related measures including exercise level and Dartmouth quality of life physical fitness scale (35). Further, the findings showed that a shorter waiting period for cardiac rehabilitation after clinical coronary revascularization increases the health benefits of patients with coronary heart disease, such as optimizing cardiopulmonary function (peak oxygen uptake VO2peak; β=−0.165, P<0.001) (36). This implies that individuals with AMI should begin a cardiac rehabilitation exercise immediately after hospital discharge to minimise risks of recurrence of cardiac events, reduce mortality risk, and improve quality of life (37).

## Modality of exercise training in cardiac rehabilitation after AMI

Aerobic exercise training (AET) is the main exercise type in cardiac rehabilitation. AET improves health-related quality of life and several physiological parameters including cardiorespiratory fitness, cardiac function, handgrip strength, and knee extension strength (38). The Exercise in Left Ventricular Dysfunction (ELVD) trial evaluated efficacy of exercise in patients with a first Q wave MI and a left ventricular ejection fraction (LVEF) below 40% and the results indicated that AET improved the quality of life of patients (39). Previous findings showed that 6-month AET markedly increased aerobic fitness and LVEF which are independent predictors of mortality in CVD patients (40, 41).

Studies have reported resistance training (RT) and AET result in a similar reduction (10%) in mortality rate in MI mice (42). To increase the additional benefits of RT for patients with CVD, including those with MI and AMI, such as improved glucose metabolism, body composition, bone mineral density, muscle strength, and endurance (43, 44), RT is mostly recommended in combination with AET (44-46). Several studies have explored the benefits of combination of RT with traditional AET. A previous RCT of 26 MI patients was conducted with patients randomly assigned to AET with high-intensity group or to combined AET and RT group. The results showed that LVEF (47), peak V̇O2 and quality of life (48) were significantly improved in the combined group compared with the values in the AET group. Moreover, a Cochrane meta-analysis comprising 10,794 CAD patients showed that combination of AET and RT was associated with a 13% and 26% reduction in all-cause and cardiovascular mortality, respectively, and a 31% reduction in hospital readmission (49).

## Dose of exercise in cardiac rehabilitation after AMI

High-intensity interval (HIIT) and moderate-intensity continuous (MICT) training are complementary training modalities recommended by most exercise prescription guidelines for CAD patients (46, 50, 51). Several meta-analyses have demonstrated that HIIT has similar or even higher benefits compared with MICT in improving peak O2 (52, 53). A previous RCT (54) compared the effect of a 12-week HIIT to MICT in post-ACS patients (< 6 weeks, 89% with MI) on the risk factors for arrhythmic death (*i.e.* heart rate recovery, heart rate variability, occurrence of ventricular arrhythmias, and QT dispersion (55, 56). The findings demonstrated that the two training interventions had no effects on these risk factors for arrhythmic death. Notably, a higher volume of exercise with MICT is required to achieve the same degree of reduction in all-cause and cardiovascular mortality observed with HIIT (57) .

These findings indicate that an exercise training program should include moderate-to-high intensity AET and RT to markedly improve survival and quality of life in patients following MI. HIIT is a promising modality of exercise, owing to the lower dose of training needed to achieve the same magnitude of benefit as AET. Although HIIT is considered safe and effective in low-risk post-acute coronary syndrome patients, further research should be conducted to determine the safety in patients with AMI patients.

# Irisin: relation with cardiac rehabilitation-mediated protection

The novel myokine, irisin is a peptide obtained from hydrolysis of the transmembrane protein fibronectin type III domain protein 5 (FNDC5). Irisin has been found in both mouse and human serum following hydrolysis of FNDC5, and can be secreted in multiple tissues (58). Studies report that irisin is highly expressed after exercise, with plasma irisin levels peaking at 6 h after exercise, and returning to pre-exercise levels within 24 h, thereby mediating the beneficial effect of exercise (59, 60). The effects of irisin in different tissues is dependent on metabolic phenotype. For instance, irisin levels in adipose tissue are significantly higher following HIIT compared with the levels after MICT in rats with dysregulated metabolic profile. However, the profile of irisin in skeletal muscle is not different after HIIT or MICT intervention. This implies that HIIT has protective effects against obesity and promotes metabolic dysfunction-induced reductions in adipose irisin levels (61).

## Relationship between irisin and acute and chronic physical activity levels

### In animals

Animal experiments have been conducted in the last 5-years to evaluate the effects of exercise patterns on irisin concentrations (**Table 1**). The experimental animal models included healthy, obesity (most), diabetic, aging, Alzheimer’s, and AMI. Three studies(60, 62, 63) focused on the impact of acute exercise, and the results showed that irisin acts as an acute exercise effector and high expression of irisin was mainly detected in blood or muscle. Further, the effector of chronic exercise training was irisin or FNDC5 (24, 64, 65), both detected in most tissues and organs. Notably, the expression patterns of irisin or FNDC5 were independent of the type of exercise (MICT, AET, RT) and intensity or duration of the exercise. Findings on the profile of FNDC5 after exercise are not consistent. Training leads to a higher concentration of FNDC5 in hippocampus of Alzheimer's mice (24). In addition, training upregulates expression of FNDC5 at protein and/or mRNA level in bone or muscle tissue in obese or normal members (65-67). However, some studies report that exercise training only upregulated FNDC5 protein content in skeletal muscles, but not its mRNA expression (64).

### Clinical studies

The ABCD study conducted in a general population demonstrated that irisin concentration is positively correlated with daily levels of physical activity (68). In addition, irisin concentration was correlated with gender (69). Studies report that resting irisin concentration is higher in females compared with the level in males (70). Only few studies have explored response of irisin levels in patients with metabolic diseases undertaking different types of exercise. Findings from small sample clinical study showed no difference in exercise-induced (including high-intensity interval exercise, continuous moderate-intensity exercise, and resistance exercise) circulating irisin levels between healthy individuals and subjects with metabolic syndrome. This finding implied that the beneficial effects of exercise on glucolipid metabolism in patients with metabolic syndrome may be partly achieved by upregulation of irisin expression (20).

Six RCTs conducted from 2016 to 2021 explored the effect of various exercise modes on irisin expression, mainly in age-related, metabolic disease (obesity (71), progressive multiple sclerosis (72), non-alcoholic fatty liver disease models (73), and healthy young individuals (74). The findings from these studies are summarized in **Table 2**. The findings from RCT studies indicated that exercise significantly upregulated expression of irisin (71-73, 75, 76). Although further studies are required to verify these findings, these effects are possibly independent of exercise mode and duration of exercise. Notably, RT and combined exercise (CT) showed a higher increase in irisin levels relative to the levels in the aerobic exercise group (73). Moreover, RT and CT significantly improved metabolism and anthropometric indexes compared with the control (77). These findings further confirm that exercise upregulates irisin level, implying that irisin is an effector molecule of exercise.

## Relationship between irisin concentration and cardiovascular disease

Findings from animal experiments indicate that irisin is highly secreted in the myocardium (10). Reduction of irisin concentration following AMI was first explored through animal experiments, even within 2 hours post-AMI (78). The findings showed that low irisin content is correlated with high expression level of markers representing myocardial damage (such as troponin and creatine phosphokinase-myocardial band isoenzyme). Several studies report similar findings in human trials (79, 80). A cross-sectional study reported that the level of serum irisin in patients with coronary artery disease (CAD) was significantly lower relative to the level in the control, indicating that it is a potential independent predictor for CAD (81). Moreover, findings from a non-randomized, interventional study showed a significant negative correlation between circulating irisin and the degree of stenosis (79).

Myocardial hypoxia occurs after infarction. Compensatory reduction of irisin level induces reduction in ATP utilization and improves energy supply of ischemic myocardium (78). However, reduction in irisin levels is exacerbated by aggravation of myocardial ischemia and hypoxia due to significant loss in myocardium, which induces ventricular remodeling and ultimately leads to heart failure (82, 83). It is therefore inferred that moderate supplementation with irisin may help to improve post-infarction cardiac function.

## Irisin plays a protective role in CVD

Previous findings indicate that expression of irisin is downregulated in some metabolic diseases, such as diabetes (84). Stimulation of irisin may be an important molecular mechanism of metformin, a conventional drug for diabetes (85). Irisin plays an important role in reduction of CVD risk factors and maintenance of cardiac function (86, 87). However, it has also been suggested that abnormally high values of circulating irisin may be associated with increased risk factors for cardiovascular disease (87) and may predict major adverse cardiovascular events in patients with acute coronary syndrome (ACS) (88). In contrast, most recent animal studies and studies using myocardial cell culture reported that exogenous irisin intervention effectively improved vascular endothelial function and impaired cardiac function under pathological conditions. To compare the recent studies on myocardial protection with irisin, the author lists them in **Table 3**.

Administration of irisin (0.5 μg/g body weight/day) in models of endothelial structural and functional abnormalities significantly reduces atherosclerosis in apolipoprotein E-deficient mice by reducing levels of inflammation and apoptosis (89). Moreover, acute intravenous injection of irisin (10 μg/kg) reduces blood pressure in spontaneously hypertensive rats by promoting NO production and endothelial NO synthase (eNOS) phosphorylation in endothelial cells (90). Furthermore, determination of endothelium-dependent vasodilation shows that intraperitoneal injection irisin (0.5 μg·g−1·day−1) daily in the morning for 8 weeks improves impaired endothelial function of the aorta caused by obesity (91). In addition, irisin treatment (microinjected into the nucleus ambiguous) promotes neuronal depolarization through the blood-brain barrier and reduces abnormal heart rate response through central cardiovascular regulation (92).

Findings from animal and cell studies indicate that administration of exogenous irisin alleviates function injury of various organs such as the liver (93), intestines (94), pulmonary (95), cerebral (96), kidney (97), and heart (15, 98) caused by ischemia and reperfusion. Previous findings indicate that the protective effect of irisin is attributed to its anti-inflammatory effect (82, 99, 100), anti-oxidative stress activity (101) and effect on reducing endothelial injury (102). Recent studies reported that irisin plays an important role in alleviating tissue fibrosis (103, 104), improving mitochondrial function (93, 105) and promoting angiogenesis (106, 107). Further, treatment of in the MI model with irisin (intraperitoneal injection or extracellular incubation) significantly reduces the level of cardiomyocyte apoptosis and myocardial infarct size, as well as significantly improves mitochondrial function, thus promoting recovery of ventricular function (12, 15, 108-115). NKX2.5 + CPCs isolated from mouse embryonic stem cells were pre-treated with irisin and implanted into a myocardial infarction tissue. The findings showed significant increase in cardiac remodeling in post-MI hearts treated with irisin compared with controls (NKX2.5 + CPCs without irisin) (113). The cardiac function and the related pathological indicators of AMI in mice treated with or without irisin were compared and the results showed that irisin reduced the area of MI and improved the cardiac function by activating ERK signaling pathways and promoting angiogenesis (112). Exercise upregulates the low expression of cardiac irisin caused by MI and further improves impaired cardiac function and renal function in animal MI rehabilitation model (23, 116).

# Possible mechanisms of the role of irisin in AMI rehabilitation

A previous study reported that exogenous irisin had therapeutic potential for pathologies associated with inflammation, oxidative stress, and apoptosis (117), but its receptor had not been identified. Recent studies have reported that simultaneous knockdown of integrins αV and β5 significantly attenuates the antioxidant/nitrosative stress and anti-apoptotic effects of irisin on H9C2, while pretreatment of adipose tissue-derived mesenchymal stromal cells (ADSCs) with irisin can promote ischemic cardioprotective effects by binding to cardiac integrins αV/β5 to induce the release of chemokine CSF2 from ischemic hearts and promotes the cardiac homing of ADSCs. It is therefore speculated that integrin αV/β5 may mediate the cardioprotective effects of irisin. However, the specific mechanisms involved in cardioprotection by irisin and its associated receptors still need to be verified by numerous studies. Mechanisms of irisin in cardiac protection reported in the past 5 years are summarized in **Table 4**.

## Inflammation

Exercise-induced irisin expression is implicated in regulation of several cardiovascular and metabolic conditions, and the therapeutic effect is partly attributed to the anti-inflammatory effects of irisin (118). Findings from a human study confirmed that exercise-induced high irisin secretion is implicated in reduction in arterial stiffness and improvement of endothelial function through activation of the arterial AMPK/Akt/eNOS pathway in obesity (119). Further animal experiments showed that irisin treatment significantly alleviates endothelial dysfunction in diabetic mice and downregulates mRNA expression of macrophages and T lymphocytes in atherosclerotic plaques as well as expression of inflammatory cytokines (IL-6, TNF-α) in aortic tissue, which further abrogates development of atherosclerosis, and analysis showed that these anti-inflammatory effects are correlated with activation of the AMPK/PI3K/PKB/eNOS pathway by irisin (26). Moreover, exogenous irisin supplementation in animal models has a direct therapeutic effect on atherosclerotic diseases by suppressing ox-LDL-induced cell inflammation and apoptosis. This therapeutic effect is attributed to inhibition of ROS/p38MAPK/NF-κB signaling (89), and/or ROS/NLRP3 inflammasome signaling (100).

## Antioxidation (inhibition of necrosis and apoptosis)

Irisin plays a protect role against cardiomyocytes and vascular endothelial cells by reducing oxidative stress through AMPK-PI3K-Akt-eNOS-ROS pathway (117). A study using myocardial ischemia-reperfusion mice model showed that irisin treatment significantly increased activity of antioxidant factors such as SOD-1 and p38 and markedly reduces of myocardial infarct size (15) Moreover, irisin overexpression or irisin treatment exhibited cardioprotective effect by inhibiting ROS and upregulating expression of antioxidant molecules such as GSH and total SOD in acute and chronic cardiotoxicity models. The results showed that therapeutic activity of irisin was mediated through the AKT/GSK3β/FYN/Nrf2 axis (101). A recent study revealed that aerobic exercise alleviated the levels of oxidative stress and apoptosis in Type II cardiorenal syndrome (CRS II) model, which was partially mediated by increase in irisin secretion (116).

## Irisin maintains mitochondrial function/structure

Abnormal structure and function of mitochondria and the resulting energy metabolism disorder plays a key role in cellular energy stress and apoptosis (120). Studies report that the protective effect of irisin on the injured myocardium due to cardiotoxicity or abnormal oxygen supply is attributed to improved mitochondrial function, autophagy regulation, and reduced apoptosis (101, 109). Exercise-induced irisin activated mitophagy and reduced MI area in a MI mice model and exhibited protective effects against cardiac function (23). These findings indicate that mitophagy is a potential mechanism through which exercise rehabilitation alleviates infarction. This finding was confirmed in other ischemia/reperfusion injury models, whereby irisin treatment restored integrity of the structure of mitochondria (by suppressing the opening of mitochondrial permeability transition pore and mitochondrial swelling) and restored mitochondrial respiration function (15, 121). Recent studies report exogenous irisin administration alleviates pressure overload-induced cardiac hypertrophy by activating ULK1 autophagy pathway, whereas endogenous irisin knockout disrupts mitochondrial homeostasis and significantly decreases cardiac differentiation in mouse embryonic stem cells (122, 123).

## Angiogenesis

A previous study treated human microvascular endothelial cells (HUVEC) and transgenic TG (fil1: GFP) zebrafish with human recombinant irisin. The findings showed that administration of exogenous irisin upregulated expression of MMP-2 and MMP-9 (interstitial metalloproteinases) in vascular endothelial cells. This finding indicated that irisin modulates vascular growth of endothelial cells by regulates ERK pathway (106). Similarly, irisin could inhibit oxidized low-density lipoprotein (oxLDL) impaired angiogenesis by modulating ERK signaling pathways (124). A recent animal study reported that administration of irisin after AMI reduces myocardial infarction size and improves cardiac function after MI (112). The therapeutic effect of irisin was attributed to the angiogenic effect mediated by HUVEC migration, which may be dependent on ERK pathway activation. However, studies have not fully explored the mechanisms underlying the effect of exercise-induced irisin vascular endothelial function.

## Anti-fibrosis

The phenotype study found that irisin administration can significantly ameliorates fibrotic remodeling in post-MI hearts and alleviated injured cardiac function (114). Mechanistic studies reported that both myocardial FNDC5 overexpression and exogenous irisin administration attenuated cardiac adverse structural remodeling due to diabetes, including myocardial fibrosis, and that its protective effects were closely associated with activation of integrin αVβ5-AKT signaling and attenuation of oxidative/nitrosative stress (125). Further study found irisin treatment inhibited TGF‐β/Smad signaling and high glucose‐induced cardiac endothelial‐to‐mesenchymal transition (EndMT), which contribute to cardiac fibrosis and heart failure (126). It has also been suggested that this protection mechanism may be the result of Nrf2 mediated inhibition of oxidative stress in angiotensin Ⅱ related myocardial fibrosis model (103). Mice transverse aortic constriction (TAC)-induced cardiac hypertrophy model reported irisin treatment attenuates pressure overload-induced cardiac hypertrophy and fibrosis mainly through regulating AMPK-mTOR signaling or inhibiting NOD-like receptor protein 3 (NLRP3) -mediated pyroptosis activation (127, 128). A recent study revealed that irisin as a mediator of the beneficial effects of exercise in cardioprotection like ameliorate EndMT through inhibiting activation of NF-κB-Snail pathway due to excessive accumulation of UCP2 and ROS and regulating the autophagy disorders (129).

In summary, these findings show that irisin (including exercise-induced irisin secretion) exerts a myocardial protective role through its anti-inflammation activity, antioxidant stress effect, and anti-apoptosis properties, as well as improving mitochondrial function, promoting angiogenesis and fibrotic remodeling. This indicates that irisin has high therapeutic and rehabilitation potential for treatment of patients post-MI. Further studies should explore the mechanism through which exercise prevents and alleviates heart disease and the role of irisin induced by exercise in these mechanisms.

# Conclusion and prospect

Exercise-based cardiac rehabilitation is an effective cardioprotective intervention strategy for patients with CVD (32, 130). The protective effects of exercise on ischemic heart are partly mediated by vascular adaptations, mitochondrial biogenesis, as well as stimulation of skeletal and cardiac muscle tissue to release myokines including irisin (131). Irisin treatment improves outcomes of CVD, which is associated with its properties of reversing inflammation, oxidative stress and excessive apoptosis, implying that irisin is a promising therapeutic target for treatment of CVD. Notably, exercise can improve cardiac function following MI by upregulating myocardial irisin expression (irrespective of exercise mode). However, the exact mechanism has not been elucidated, and multiple clinical and animal studies should be conducted to explore the role of irisin in MI rehabilitation **(Figure 1)**. In addition, studies should evaluate whether Irisin-related agents can be supplemented to improve clinical benefits in patients who are intolerant to exercise after MI. This review provides a possible reference for a therapeutic target for exercise rehabilitation in MI patients.

# Figure

图示

描述已自动生成

**Figure 1.** Exercise exhibits cardioprotective effect against post-myocardial infarction by mediating irisin expression and the potential mechanisms. Exercise and exogenous intervention with irisin can improve impaired cardiac function after MI by inhibiting inflammation and oxidative stress, and further improving the abnormalities of autophagy, apoptosis, and mitochondrial function, promoting angiogenesis, and inhibiting fibrotic remodeling caused by infarction. Meanwhile, exercise is an effective stimulus for upregulating irisin expression, however, whether exercise exerts the above beneficial effects through mediating irisin still needs to be verified by numerous studies. AMPK, adenosine 5’-monophosphate-activated protein kinase; PI3k, phosphoinositide 3-kinase; AKT, protein kinase B; eNOS, endothelial nitric oxide synthase; Bax, bcl2-associated x; mTOR, mammalian target of rapamycin; IL-1β, interleukin-1β; IL-18, interleukin-18; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; ROS, reactive oxygen species; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa-B; NLRP3, nucleotide-binding oligomerization domain (Nod)-like receptor protein 3; MDA, malondialdehyde; SOD-1, superoxide Dismutase-1; GSK3β, glycogen synthase kinase-3β; Nrf2, NF-E2-related factor; OPA1,optic atrophy 1; ULK1, uncoordinated 51-like kinase 1; NRF1, nuclear respiratory factor; PGC1‐α, peroxisome proliferator-activated receptor-γ coactivator-1 alpha; ERK, extracellular regulated protein kinases; MMP-2, matrix metallo-proteinase-2; MMP-9, matrix metallo-proteinase-9; EndMT, endothelial-to-mesenchymal transition.

# Tables

**Table 1.** Study characteristics of animal experiments that explored the effects of exercise on circulating irisin concentrations.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author(year)** | **Subjects** | **Test area** | **Irisin (FNDC5) Level** | **Exercise mode** |
| Seo D.Y. (2020) (21),  Khalafi M. (2020) (132),  Tine Kartinah N (2018) (61),  Kazeminasab F. (2018) (64) | Rat, Mouse | Circulating, adipose  FNDC5 protein | ↑ | MICT treadmill, 8,12w |
| Shirvani H. (2020) (133)  Babaei, A. (2021) (134) | Rat | Circulating  Hippocampal | ↑ | MICT running 6w, 8w |
| Siteneski A. (2020) (135)  Gruhn, K. (2021) (136) | Rat  Mouse | Hippocampus | ↑ | MICT treadmill, speed increase, 4w |
| Siteneski A. (2020) (135) | Rat | Circulating | ↑ | LICT treadmill, speed increase, 4w |
| Hassaan P.S (2019) (137) | Rat | Skeletal | ↑ | LICT, treadmill, 8w |
| Khalafi M.(2020) (132),  Shirvani H (2019) (138),  Amri J. (2019) (139),  Tine Kartinah N (2018) (61) | Mouse Rat | Circulating, adipose | ↑ | HIIT treadmill, 8,10,12w |
| Kubo H. (2019) (140) | Mouse | Circulating | ↑ | HIIT treadmill, speed increase, 12w |
| Shirvani H. (2020) (133) | Rat | Circulating | ↑ | HIIT running 8w |
| Liu (2021) (141) | Rat | Biceps brachii and surrounding fatty tissue | ↑ | high-intensity interval static training, 8w |
| Nadermann N. (2020) (142) | Goldfish | Muscle | ↑ | High intensity acute exercise, swimming, 30min |
| Pang (2018) (60) | Mouse | Circulating | ↑ | Moderate acute treadmill, 30-60min |
| Cho, E (2021) (143) | Mouse | Soleus and gastrocnemius muscle | ↑ | Acute Swimming 90min |
| Hegazy, M. A. (2022)(144)  Lourenco M.V. (2019) (24)  Schaalan M.F (2018) (145) | Rat Mouse | Hippocampi, muscle FNDC5 mRNA, circulating | ↑ | Swimming 4w, 5w, 6w,8w |
| Belviranli M. (2018) (146),  Uysal N (2018) (147),  Zhang J. (2017) (65) | Mouse  Rat | Cardiac and hepatic, circulating, brain, brown/ white adipose tissue, kidney, and pancreas, bone (FNDC5/irisin protein, mRNA) | ↑ | Voluntary wheel 2w, 6w,12w |
| Li (2021) (23)  Tavassoli H.(2019) (148)  Kim HJ (2017) (149) | Rat  Mouse | Circulating  Soleus muscles  Cardiac | ↑  ↓  ↑ | RT, climb ladder, 8w, 12w |
| Zhao (2021) (150)  Amri J. (2019) (139)  Bastu. E (2017) (151) | Rat  Mouse | Circulating | ↑ | endurance training, 8w, 10w |
| Mazur-Bialy A.I.(2017) (152)  Li (2017) (18)  Zhu (2021) (153) | Mouse  Rat | Circulating,  Skeletal muscle | ↑ | Moderate endurance, treadmill or voluntary wheel, 8w |
| Guiford BL (2017)(154) | Mouse | Muscle | ↓ | Endurance voluntary wheel, 4w |
| Babaei P (2017) (155) | Rat | Circulating | ↑ | MICT and endurance, treadmill 8w |

MICT, moderate-intensity continuous training; HIIT, high-intensity interval training; LICT, low intensity continuous training; RT, resistance training.

**Table 2.** Characteristics of randomized-controlled trials that explored the effects of exercise on circulating irisin concentrations in adults.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author (year)** | **Participants** | **Age means (SD), exercise/control** | **Exercise mode** | **Irisin level** |
| Briken S (2016) (72) | Patients with  progressive multiple sclerosis | 49.9 (7.6) / 50.4 (7.6) | End, Acute and Chronic, 9 w | No sig |
| Bonfante IL (2017) (76) | Obese men | 49.1(5.46) / 49.1(6.33) | RT and End, (55–85 % peak V̇O2), 24 w | ↑ (Avoid reducing) |
| Qiu (2018) (74) | Healthy young adults | 27.4 (3.8) / 24.7 (2.5) | acute exercise 80% peak V̇O2, 50 min and exhaustion | ↑ |
| Jia (2018) (73) | Patients with non-alcoholic fatty liver disease | 54.62 (7.54) of aerobic / 55.18 (7.48) of resistance /54.24 (7.51) of control | AET and RT, moderate intensity, 6 m | ↑ |
| Weber-Rajek M (2019) (71) | Overweight or Obese Elderly Women with Stress Urinary Incontinence | 62.5 (IQR: 2.0) /67.0 (IQR:6.0) | Pelvic floor muscle training, 4 w | ↑ |
| Amanat S. (2020) (77) | Overweight women with metabolic syndrome | 54.5 (6.9) | AET, RT, and CT, 12w | ↑ |

RT, resistance training; End, endurance training; AET, aerobic training; CT, combined exercise; W, week; m, month; V̇O2, oxygen uptake; IQR, interquartile range; HIIT, high-intensity interval training.

**Table 3.** Myocardial protective effect of irisin.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author (year)** | **Irisin interventions** | **Subjects** | **Models** | **Effect** |
| Pan, J. A. (2021) (129) | i.p. injection, 2 wk | Male 5-wk-old C57BL/6J mice | doxorubicin -induced cardiotoxicity | Improve endothelial dysfunction |
| Liu (2018) (126) | i.p. injection, 16 w  pre-incubation, 8 h | Mice and HUVECs | Diabetic cardiomyopathy |
| Yan (2022) (156) | i.p. injection, 5times | Mouse and Rat | Ischemia- reperfusion | Improve myocardial ischemia and hypoxia injury and dysfunction |
| Fan (2020) (110) | Incubation,25h | H9C2 | Hypoxia/  reoxygenation |
| Xin (2020) (111),  Liao (2019) (112) | Incubation  i.p. injection, 2w and incubation 24h | Primary cardiomyocytes  Male mice and HUVECs | Myocardial infarction |
| Zhao (2019) (113) | Incubation 24h | CD-1 mice and Nkx2.5+ CPCs |
| Deng (2020) (114) | Incubation 48h,  overexpression | Fluc+–eGFP+ transgenic mice and BM-MSCs |
| Ouyang (2020) (12) | Injection and incubation | Mst1 transgenic mice and Primary cardiomyocytes | LPS-mediated septic cardiomyopathy |
| Li (2019) (115) | Overexpression and incubation 48h | Irisin-Tgmice, primary cardiomyocytes | TAC induced cardiac hypertrophy |
| Hu (2022) (157) | Overexpression and subcutaneously infused 14d | Young mice and  Neonatal rat cardiomyocytes | Aging induced cardiac hypertrophy |
| Islam, M. R. (2021) (158) | AAV8-irisin-FLAG injection, once | Genetic deletion of Fndc5/irisin mice | Ageing or Alzheimer’s disease | Improve neuroregulation |
| Bretland, K. A. (2021) (159) | i.p. injection, 4 w | Age-related tauopathy |

I.P., intraperitoneal; I.V., intravenous; ICV, intracerebroventricular; BM-MSCs, bone marrow mesenchymal stem cells; LPS, lipopolysaccharide; TAC, transverse aortic constriction; Tg, transgenic.

**Table 4.** Possible mechanisms of the protective effect of irisin against CVD

|  |  |  |  |
| --- | --- | --- | --- |
| **Author (year)** | **Experiment model** | **Possible mechanisms/**  **signalling pathways** | **Protective effect** |
| Hu (2022) (157) | Aging-related cardiac dysfunction in mouse | ↓Lysosomal degradation of GLP-1R and ↑AMPKα  ↓NLRP3 | Anti-inflammatory |
| Li (2021) (160) | Sepsis-induced cardiac dysfunction in mouse | ↓TLR4 and NLRP3 inflammasome signalings, ↓IL-1β, TNF-α, and IL-6 |
| Ning (2021) (161) | MI hearts in mouse | ↑Nrf2/HO-1 axis and  ↓NF-κB signaling pathway |
| Lin (2021) (125) | Diabetic cardiomyopathy mouse | ↑Integrin αVβ5-AKT signaling  ↓iNOS/NOX2 | Anti-oxidative stress (inhibition of apoptosis) |
| Deng (2018) (100) | HUVECs in AGEs medium | ↓ROS, MDA, IL-1β and IL-18 |
| Yan (2022) (156) | Myocardial I/R injury in mouse | ↑Integrin αV/β5, Csf2rb, ERK1/2-SOD2 |
| Jiang (2021) (16) | Lipopolysaccharide-stimulated cardiomyocytes | ↓Bax, caspase-3 and Fundc1 |
| Zhang (2020) (101) | DOX-induced cardiotoxicity  in mouse | ↑AKT/GSK3β/FYN/Nrf2 pathway |
| Fan (2020) (110) | Hypoxia-reoxygenation injury  in hyperglycemia-treated cardiomyocytes | ↑AMPK pathway  (↓LDH release) | Maintain mitochondrial function/structure,  Suppress mitochondrial apoptosis |
| Xin (2020) (111) | Infarcted hearts in vivo and hypoxia-treated cardiomyocytes  in vitro | ↑Opa1-induced mitophagy |
| Li (2018) (122) | TAC-induced myocardial hypertrophy in mouse | ↑AMPK-ULK1 |
| He (2021) (22) | Radiation-induced heart disease in mouse | ↑DRP1, PINK1 and LC3B |
| Nazem (2018) (123) | Fndc5 knockdown in mice embryonic stem cell | ↑PGC1-α |
| Zhang (2019) (124) | HUVECs and HMEC-1 were treated with oxLDL, Matrigel plug angiogenesis assay and CAM model | ↑AKT/mTOR/S6K1//Nrf2 pathway | Promotes Angiogenesis |
| Liao (2019) (112) | Acute MI mouse | ↑ERK pathway |
| Yan (2022) (156) | Myocardial I/R injury in mouse | ↑Integrin αV/β5, Csf2rb, ERK1/2-ANGPTL4 |
| Pan (2021) (129) | Doxorubicin induced cardiotoxicity in mouse | ↓ROS, EndMT and UCP2  ↓NF-κB-Snail pathway | Anti-fibrosis |
| Lin (2021) (125)  Liu (2018) (126) | Diabetic cardiomyopathy in mouse | ↑integrin αVβ5-AKT pathway  ↓EndMT  ↓TGF-β/Smad signalling |
| Chen (2019) (103) | Angiotensin II-related cardiac fibrosis in mouse | ↓ROS/ TGFβ1/Smad2/3 signaling  ↓Nrf2 |
| Yu (2019) (127)  Yue (2021) (128) | TAC - induced cardiac hypertrophy in mouse | ↑AMPK-mTOR signaling  ↓NLRP3-mediated pyroptosis |

TLR4, toll-like receptor 4; NLRP3, nucleotide-binding oligomerization domain (Nod)-like receptor protein 3; TLR4, toll-like receptor 4; HO-1, heme oxygenase-1; HUVECs, human umbilical vein endothelial cells; AGEs, advanced glycation end products; TAC, transverse aortic constriction; ISV, intersegmental vessel; CAM, chicken embryo membrane; AMPK, adenosine 5’-monophosphate-activated protein kinase; PI3k, phosphoinositide 3-kinase; AKT, protein kinase B; eNOS, endothelial nitric oxide synthase; Bax, bcl2-associated x; mTOR, mammalian target of rapamycin; 4EBP1, 4E-binding protein 1; HSP20, heat shock protein 20; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; ICAM-1, intercellular cell adhesion molecule-1; VCAM-1, vascular cell adhesion protein 1; MCP-1, macrophage chemoattractant protein-1; ROS, reactive oxygen species; iNOS, inducible nitric oxide synthase; NOX2, NADPH oxidase 2; MDA, malondialdehyde; IL-1β, interleukin-1β; IL-18, interleukin-18; SOD-1, superoxide Dismutase-1; GSK3β, glycogen synthase kinase-3β; Nrf2, NF-E2-related factor; LDH, lactate dehydrogenase; OPA1,optic atrophy 1; ULK1, uncoordinated 51-like kinase 1; LPS: lipopolysaccharide; PINK1, PTEN induced putative kinase 1; PGC1‐α, peroxisome proliferator-activated receptor-γ coactivator-1 alpha; ERK, extracellular regulated protein kinases; ANGPTL4, Angiopoietin-likeProtein4; EndMT, endothelial-to-mesenchymal transition; TAC, transverse aortic constriction; NLRP3, NOD-like receptor protein 3; CMECs, cardiac microvascular endothelial cells.

# Conflict of Interest

*The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest*.

# Author Contributions

S.Q. and Z.T. contributed to the conception or design of the work. S.Q. contributed to writing the original draft, reviewing and editing. M.B. and B.B. contributed to writing the original draft and reviewing. G.L., D.T. and Z.T. critically revised the manuscript. All gave final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy.

# Funding

National Natural Science Foundation of China, Grant/Award Numbers: 32171128

# References

1. Lear SA, Hu W, Rangarajan S, Gasevic D, Leong D, Iqbal R, et al. The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet. 2017;390(10113):2643-54.

2. Lin H, Sardana M, Zhang Y, Liu C, Trinquart L, Benjamin EJ, et al. Association of Habitual Physical Activity With Cardiovascular Disease Risk. Circ Res. 2020;127(10):1253-60.

3. Franklin BA, Thompson PD, Al-Zaiti SS, Albert CM, Hivert MF, Levine BD, et al. Exercise-Related Acute Cardiovascular Events and Potential Deleterious Adaptations Following Long-Term Exercise Training: Placing the Risks Into Perspective-An Update: A Scientific Statement From the American Heart Association. Circulation. 2020;141(13):e705-e36.

4. Aengevaeren VL, Mosterd A, Braber TL, Prakken NHJ, Doevendans PA, Grobbee DE, et al. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017;136(2):138-48.

5. Maessen MF, Eijsvogels TM, Stevens G, van Dijk AP, Hopman MT. Benefits of lifelong exercise training on left ventricular function after myocardial infarction. Eur J Prev Cardiol. 2017;24(17):1856-66.

6. Alhumaid W, Small SD, Kirkham AA, Becher H, Pituskin E, Prado CM, et al. A Contemporary Review of the Effects of Exercise Training on Cardiac Structure and Function and Cardiovascular Risk Profile: Insights From Imaging. Front Cardiovasc Med. 2022;9:753652.

7. Pinckard K, Baskin KK, Stanford KI. Effects of Exercise to Improve Cardiovascular Health. Front Cardiovasc Med. 2019;6:69.

8. Rosenkilde M, Rygaard L, Nordby P, Nielsen LB, Stallknecht B. Exercise and weight loss effects on cardiovascular risk factors in overweight men. J Appl Physiol (1985). 2018;125(3):901-8.

9. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-8.

10. Aydin S, Kuloglu T, Aydin S, Eren MN, Celik A, Yilmaz M, et al. Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: cardiac muscle produces more irisin than skeletal muscle. Peptides. 2014;52:68-73.

11. Xin C, Zhang Z, Gao G, Ding L, Yang C, Wang C, et al. Irisin Attenuates Myocardial Ischemia/Reperfusion Injury and Improves Mitochondrial Function Through AMPK Pathway in Diabetic Mice. Front Pharmacol. 2020;11:565160.

12. Ouyang H, Li Q, Zhong J, Xia F, Zheng S, Lu J, et al. Combination of melatonin and irisin ameliorates lipopolysaccharide-induced cardiac dysfunction through suppressing the Mst1-JNK pathways. J Cell Physiol. 2020;235(10):6647-59.

13. Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324-37.

14. Wang J, Zhao YT, Zhang L, Dubielecka PM, Zhuang S, Qin G, et al. Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation (Lepr(db) ) Mice. Front Pharmacol. 2020;11:769.

15. Wang H, Zhao YT, Zhang S, Dubielecka PM, Du J, Yano N, et al. Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury. J Cell Physiol. 2017;232(12):3775-85.

16. Jiang X, Cai S, Jin Y, Wu F, He J, Wu X, et al. Irisin Attenuates Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in the H9C2 Cellular Model of Septic Cardiomyopathy through Augmenting Fundc1-Dependent Mitophagy. Oxid Med Cell Longev. 2021;2021:2989974.

17. Silvestrini A, Bruno C, Vergani E, Venuti A, Favuzzi AMR, Guidi F, et al. Circulating irisin levels in heart failure with preserved or reduced ejection fraction: A pilot study. PLoS One. 2019;14(1):e0210320.

18. Li D-J, Li Y-H, Yuan H-B, Qu L-F, Wang P. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism. 2017;68:31-42.

19. Kim H, Wrann CD, Jedrychowski M, Vidoni S, Kitase Y, Nagano K, et al. Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors. Cell. 2018;175(7):1756-68.e17.

20. Huh JY, Siopi A, Mougios V, Park KH, Mantzoros CS. Irisin in response to exercise in humans with and without metabolic syndrome. J Clin Endocrinol Metab. 2015;100(3):E453-7.

21. Seo DY, Bae JH, Kim TN, Kwak HB, Kha PT, Han J. Exercise-induced circulating irisin level is correlated with improved cardiac function in rats. International Journal of Environmental Research and Public Health. 2020.

22. He W, Tang Y, Li C, Zhang X, Huang S, Tan B, et al. Exercise Enhanced Cardiac Function in Mice With Radiation-Induced Heart Disease via the FNDC5/Irisin-Dependent Mitochondrial Turnover Pathway. Front Physiol. 2021;12:739485.

23. Li H, Qin S, Liang Q, Xi Y, Bo W, Cai M, et al. Exercise Training Enhances Myocardial Mitophagy and Improves Cardiac Function via Irisin/FNDC5-PINK1/Parkin Pathway in MI Mice. Biomedicines. 2021;9(6).

24. Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. Nat Med. 2019;25(1):165-75.

25. Wang HH, Zhang XW, Chen WK, Huang QX, Chen QQ. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. J Diabetes Complications. 2015;29(3):384-9.

26. Lu J, Xiang G, Liu M, Mei W, Xiang L, Dong J. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice. Atherosclerosis. 2015;243(2):438-48.

27. Chen J, Li K, Shao J, Lai Z, Gao R, Wang C, et al. Irisin Suppresses Nicotine-Mediated Atherosclerosis by Attenuating Endothelial Cell Migration, Proliferation, Cell Cycle Arrest, and Cell Senescence. Front Cardiovasc Med. 2022;9:851603.

28. Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol. 2022;19(3):180-94.

29. Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, et al. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiol. 2017;2(8):890-5.

30. Rosenson RS, Farkouh ME, Mefford M, Bittner V, Brown TM, Taylor B, et al. Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. J Am Coll Cardiol. 2017;69(22):2696-706.

31. Novaković M, Novak T, Vižintin Cuderman T, Krevel B, Tasič J, Rajkovič U, et al. Exercise capacity improvement after cardiac rehabilitation following myocardial infarction and its association with long-term cardiovascular events. Eur J Cardiovasc Nurs. 2022;21(1):76-84.

32. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016;67(1):1-12.

33. Haykowsky M, Scott J, Esch B, Schopflocher D, Myers J, Paterson I, et al. A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling. Trials. 2011;12:92.

34. Peixoto TC, Begot I, Bolzan DW, Machado L, Reis MS, Papa V, et al. Early exercise-based rehabilitation improves health-related quality of life and functional capacity after acute myocardial infarction: a randomized controlled trial. Can J Cardiol. 2015;31(3):308-13.

35. Fell J, Dale V, Doherty P. Does the timing of cardiac rehabilitation impact fitness outcomes? An observational analysis. Open Heart. 2016;3(1):e000369.

36. Marzolini S, Blanchard C, Alter DA, Grace SL, Oh PI. Delays in Referral and Enrolment Are Associated With Mitigated Benefits of Cardiac Rehabilitation After Coronary Artery Bypass Surgery. Circ Cardiovasc Qual Outcomes. 2015;8(6):608-20.

37. Parker K, Stone JA, Arena R, Lundberg D, Aggarwal S, Goodhart D, et al. An early cardiac access clinic significantly improves cardiac rehabilitation participation and completion rates in low-risk ST-elevation myocardial infarction patients. Can J Cardiol. 2011;27(5):619-27.

38. Izawa K, Hirano Y, Yamada S, Oka K, Omiya K, Iijima S. Improvement in physiological outcomes and health-related quality of life following cardiac rehabilitation in patients with acute myocardial infarction. Circ J. 2004;68(4):315-20.

39. Giannuzzi P, Temporelli PL, Corrà U, Gattone M, Giordano A, Tavazzi L. Attenuation of unfavorable remodeling by exercise training in postinfarction patients with left ventricular dysfunction: results of the Exercise in Left Ventricular Dysfunction (ELVD) trial. Circulation. 1997;96(6):1790-7.

40. Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, et al. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J. 2008;156(2):292-300.

41. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673-80.

42. Barboza CA, Souza GI, Oliveira JC, Silva LM, Mostarda CT, Dourado PM, et al. Cardioprotective Properties of Aerobic and Resistance Training Against Myocardial Infarction. Int J Sports Med. 2016;37(6):421-30.

43. Kirkman DL, Lee DC, Carbone S. Resistance exercise for cardiac rehabilitation. Prog Cardiovasc Dis. 2022;70:66-72.

44. Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin BA, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2007;116(5):572-84.

45. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2020:2047487320913379.

46. Price KJ, Gordon BA, Bird SR, Benson AC. A review of guidelines for cardiac rehabilitation exercise programmes: Is there an international consensus? Eur J Prev Cardiol. 2016;23(16):1715-33.

47. Farheen H, Khalid Z, Tariq MI, Sadiq T, Amjad I, Ramzan T. Combined Effect of Aerobic and Resistance Interval Training on Ejection Fraction in Myocardial Infarction. J Coll Physicians Surg Pak. 2019;29(3):290-2.

48. Khalid Z, Farheen H, Tariq MI, Amjad I. Effectiveness of resistance interval training versus aerobic interval training on peak oxygen uptake in patients with myocardial infarction. J Pak Med Assoc. 2019;69(8):1194-8.

49. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011(7):Cd001800.

50. Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol. 2012;19(5):1005-33.

51. Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol. 2013;20(3):442-67.

52. Gomes-Neto M, Durães AR, Reis H, Neves VR, Martinez BP, Carvalho VO. High-intensity interval training versus moderate-intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(16):1696-707.

53. Conraads VM, Pattyn N, De Maeyer C, Beckers PJ, Coeckelberghs E, Cornelissen VA, et al. Aerobic interval training and continuous training equally improve aerobic exercise capacity in patients with coronary artery disease: the SAINTEX-CAD study. Int J Cardiol. 2015;179:203-10.

54. Boidin M, Gayda M, Henri C, Hayami D, Trachsel LD, Besnier F, et al. Effects of interval training on risk markers for arrhythmic death: a randomized controlled trial. Clinical Rehabilitation. 2019;33(8):1320-30.

55. Freeman JV, Dewey FE, Hadley DM, Myers J, Froelicher VF. Autonomic nervous system interaction with the cardiovascular system during exercise. Prog Cardiovasc Dis. 2006;48(5):342-62.

56. Wei K, Dorian P, Newman D, Langer A. Association between QT dispersion and autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol. 1995;26(4):859-63.

57. Eijsvogels TM, Molossi S, Lee DC, Emery MS, Thompson PD. Exercise at the Extremes: The Amount of Exercise to Reduce Cardiovascular Events. J Am Coll Cardiol. 2016;67(3):316-29.

58. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61(12):1725-38.

59. Maak S, Norheim F, Drevon CA, Erickson HP. Progress and Challenges in the Biology of FNDC5 and Irisin. Endocr Rev. 2021;42(4):436-56.

60. Pang M, Yang J, Rao J, Wang H, Zhang J, Wang S, et al. Time-Dependent Changes in Increased Levels of Plasma Irisin and Muscle PGC-1α and FNDC5 after Exercise in Mice. Tohoku J Exp Med. 2018;244(2):93-103.

61. Tine Kartinah N, Rosalyn Sianipar I, Nafi'ah, Rabia. The Effects of Exercise Regimens on Irisin Levels in Obese Rats Model: Comparing High-Intensity Intermittent with Continuous Moderate-Intensity Training. Biomed Res Int. 2018;2018:4708287.

62. Nadermann N, Volkoff H. Effects of short-term exercise on food intake and the expression of appetite-regulating factors in goldfish. Peptides. 2020.

63. Bell MA, Levine CB, Downey RL, Griffitts C, Mann S, Frye CW, et al. Influence of endurance and sprinting exercise on plasma adiponectin, leptin and irisin concentrations in racing Greyhounds and sled dogs. Aust Vet J. 2016;94(5):154-9.

64. Kazeminasab F, Marandi SM, Ghaedi K, Safaeinejad Z, Esfarjani F, Nasr-Esfahani MH. A comparative study on the effects of high-fat diet and endurance training on the PGC-1α-FNDC5/irisin pathway in obese and nonobese male C57BL/6 mice. Appl Physiol Nutr Metab. 2018;43(7):651-62.

65. Zhang J, Valverde P, Zhu X, Murray D, Wu Y, Yu L, et al. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone Res. 2017;5:16056.

66. Rocha-Rodrigues S, Rodríguez A, Gouveia AM, Gonçalves IO, Becerril S, Ramírez B, et al. Effects of physical exercise on myokines expression and brown adipose-like phenotype modulation in rats fed a high-fat diet. Life Sci. 2016;165:100-8.

67. Reisi J, Ghaedi K, Rajabi H, Marandi SM. Can Resistance Exercise Alter Irisin Levels and Expression Profiles of FNDC5 and UCP1 in Rats? Asian J Sports Med. 2016;7(4):e35205.

68. Buscemi S, Corleo D, Vasto S, Buscemi C, Massenti MF, Nuzzo D, et al. Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study. Int J Obes (Lond). 2018;42(3):398-404.

69. Zügel M, Qiu S, Laszlo R, Bosnyák E, Weigt C, Müller D, et al. The role of sex, adiposity, and gonadectomy in the regulation of irisin secretion. Endocrine. 2016;54(1):101-10.

70. Anastasilakis AD, Polyzos SA, Saridakis ZG, Kynigopoulos G, Skouvaklidou EC, Molyvas D, et al. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J Clin Endocrinol Metab. 2014;99(9):3247-55.

71. Weber-Rajek M, Radzimińska A, Strączyńska A, Strojek K, Piekorz Z, Kozakiewicz M, et al. A Randomized-Controlled Trial Pilot Study Examining the Effect of Pelvic Floor Muscle Training on the Irisin Concentration in Overweight or Obese Elderly Women with Stress Urinary Incontinence. Biomed Res Int. 2019;2019:7356187.

72. Briken S, Rosenkranz SC, Keminer O, Patra S, Ketels G, Heesen C, et al. Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis. J Neuroimmunol. 2016;299:53-8.

73. Jia GY, Han T, Gao L, Wang L, Wang SC, Yang L, et al. [Effect of aerobic exercise and resistance exercise in improving non-alcoholic fatty liver disease: a randomized controlled trial]. Zhonghua Gan Zang Bing Za Zhi. 2018;26(1):34-41.

74. Qiu S, Bosnyák E, Treff G, Steinacker JM, Nieß AM, Krüger K, et al. Acute exercise-induced irisin release in healthy adults: Associations with training status and exercise mode. Eur J Sport Sci. 2018;18(9):1226-33.

75. Kim HJ, So B, Choi M, Kang D, Song W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans. Exp Gerontol. 2015;70:11-7.

76. Bonfante IL, Chacon-Mikahil MP, Brunelli DT, Gáspari AF, Duft RG, Lopes WA, et al. Combined training, FNDC5/irisin levels and metabolic markers in obese men: A randomised controlled trial. Eur J Sport Sci. 2017;17(5):629-37.

77. Amanat S, Sinaei E, Panji M, MohammadporHodki R, Bagheri-Hosseinabadi Z, Asadimehr H, et al. A Randomized Controlled Trial on the Effects of 12 Weeks of Aerobic, Resistance, and Combined Exercises Training on the Serum Levels of Nesfatin-1, Irisin-1 and HOMA-IR. Front Physiol. 2020;11:562895.

78. Kuloglu T, Aydin S, Eren MN, Yilmaz M, Sahin İ, Kalayci M, et al. Irisin: A potentially candidate marker for myocardial infarction. Peptides. 2014;55:85-91.

79. Anastasilakis AD, Koulaxis D, Kefala N, Polyzos SA, Upadhyay J, Pagkalidou E, et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism. 2017;73:1-8.

80. Emanuele E, Minoretti P, Pareja-Galeano H, Sanchis-Gomar F, Garatachea N, Lucia A. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am J Med. 2014;127(9):888-90.

81. Deng W. Association of Serum Irisin Concentrations with Presence and Severity of Coronary Artery Disease. Med Sci Monit. 2016;22:4193-7.

82. Matsuo Y, Gleitsmann K, Mangner N, Werner S, Fischer T, Bowen TS, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle. 2015;6(1):62-72.

83. Zhang X, Hu C, Wu HM, Ma ZG, Tang QZ. Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. Acta Pharmacol Sin. 2020.

84. Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm Metab Res. 2016;48(10):644-52.

85. Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxf). 2015;213(3):711-21.

86. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Makras P, Perakakis N, Kountouras J, et al. Irisin in metabolic diseases. Endocrine. 2018;59(2):260-74.

87. Calan M, Demirpence M. Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly. Hormones (Athens). 2019;18(4):435-42.

88. Aronis KN, Moreno M, Polyzos SA, Moreno-Navarrete JM, Ricart W, Delgado E, et al. Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int J Obes (Lond). 2015;39(1):156-61.

89. Zhang Y, Mu Q, Zhou Z, Song H, Zhang Y, Wu F, et al. Protective Effect of Irisin on Atherosclerosis via Suppressing Oxidized Low Density Lipoprotein Induced Vascular Inflammation and Endothelial Dysfunction. PLoS One. 2016;11(6):e0158038.

90. Fu J, Han Y, Wang J, Liu Y, Zheng S, Zhou L, et al. Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK-Akt-eNOS-NO Pathway in the Spontaneously Hypertensive Rat. J Am Heart Assoc. 2016;5(11).

91. Han F, Zhang S, Hou N, Wang D, Sun X. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway. Am J Physiol Heart Circ Physiol. 2015;309(9):H1501-8.

92. Brailoiu E, Deliu E, Sporici RA, Brailoiu GC. Irisin evokes bradycardia by activating cardiac-projecting neurons of nucleus ambiguus. Physiol Rep. 2015;3(6).

93. Bi J, Zhang J, Ren Y, Du Z, Li Q, Wang Y, et al. Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress. Redox Biol. 2019;20:296-306.

94. Du J, Fan X, Yang B, Chen Y, Liu KX, Zhou J. Irisin pretreatment ameliorates intestinal ischemia/reperfusion injury in mice through activation of the Nrf2 pathway. Int Immunopharmacol. 2019;73:225-35.

95. Chen K, Xu Z, Liu Y, Wang Z, Li Y, Xu X, et al. Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury. Sci Transl Med. 2017;9(418).

96. Jin Z, Guo P, Li X, Ke J, Wang Y, Wu H. Neuroprotective effects of irisin against cerebral ischemia/ reperfusion injury via Notch signaling pathway. Biomed Pharmacother. 2019;120:109452.

97. Zhang J, Bi J, Ren Y, Du Z, Li T, Wang T, et al. Involvement of GPX4 in irisin's protection against ischemia reperfusion-induced acute kidney injury. J Cell Physiol. 2020.

98. Gul-Kahraman K, Yilmaz-Bozoglan M, Sahna E. Physiological and pharmacological effects of melatonin on remote ischemic perconditioning after myocardial ischemia-reperfusion injury in rats: Role of Cybb, Fas, NfκB, Irisin signaling pathway. J Pineal Res. 2019;67(2):e12589.

99. Xiong XQ, Geng Z, Zhou B, Zhang F, Han Y, Zhou YB, et al. FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity. Metabolism. 2018;83:31-41.

100. Deng X, Huang W, Peng J, Zhu TT, Sun XL, Zhou XY, et al. Irisin Alleviates Advanced Glycation End Products-Induced Inflammation and Endothelial Dysfunction via Inhibiting ROS-NLRP3 Inflammasome Signaling. Inflammation. 2018;41(1):260-75.

101. Zhang X, Hu C, Kong CY, Song P, Wu HM, Xu SC, et al. FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT. Cell Death Differ. 2020;27(2):540-55.

102. Ye L, Xu M, Hu M, Zhang H, Tan X, Li Q, et al. TRPV4 is involved in irisin-induced endothelium-dependent vasodilation. Biochem Biophys Res Commun. 2018;495(1):41-5.

103. Chen RR, Fan XH, Chen G, Zeng GW, Xue YG, Liu XT, et al. Irisin attenuates angiotensin II-induced cardiac fibrosis via Nrf2 mediated inhibition of ROS/ TGFβ1/Smad2/3 signaling axis. Chem Biol Interact. 2019;302:11-21.

104. Zhou B, Ling L, Zhang F, Liu TY, Zhou H, Qi XH, et al. Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation. Cell Physiol Biochem. 2018;48(1):227-36.

105. Xie C, Zhang Y, Tran TD, Wang H, Li S, George EV, et al. Irisin Controls Growth, Intracellular Ca2+ Signals, and Mitochondrial Thermogenesis in Cardiomyoblasts. PLoS One. 2015;10(8):e0136816.

106. Wu F, Song H, Zhang Y, Zhang Y, Mu Q, Jiang M, et al. Irisin Induces Angiogenesis in Human Umbilical Vein Endothelial Cells In Vitro and in Zebrafish Embryos In Vivo via Activation of the ERK Signaling Pathway. PLoS One. 2015;10(8):e0134662.

107. Song H, Wu F, Zhang Y, Zhang Y, Wang F, Jiang M, et al. Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS One. 2014;9(10):e110273.

108. Wang Z, Chen K, Han Y, Zhu H, Zhou X, Tan T, et al. Irisin Protects Heart Against Ischemia-Reperfusion Injury Through a SOD2-Dependent Mitochondria Mechanism. J Cardiovasc Pharmacol. 2018;72(6):259-69.

109. Zhao YT, Wang H, Zhang S, Du J, Zhuang S, Zhao TC. Irisin Ameliorates Hypoxia/Reoxygenation-Induced Injury through Modulation of Histone Deacetylase 4. PLoS One. 2016;11(11):e0166182.

110. Fan J, Zhu Q, Wu Z, Ding J, Qin S, Liu H, et al. Protective effects of irisin on hypoxia-reoxygenation injury in hyperglycemia-treated cardiomyocytes: Role of AMPK pathway and mitochondrial protection. J Cell Physiol. 2020;235(2):1165-74.

111. Xin T, Lu C. Irisin activates Opa1-induced mitophagy to protect cardiomyocytes against apoptosis following myocardial infarction. Aging (Albany NY). 2020;12(5):4474-88.

112. Liao Q, Qu S, Tang LX, Li LP, He DF, Zeng CY, et al. Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis. Acta Pharmacol Sin. 2019;40(10):1314-21.

113. Zhao YT, Wang J, Yano N, Zhang LX, Wang H, Zhang S, et al. Irisin promotes cardiac progenitor cell-induced myocardial repair and functional improvement in infarcted heart. J Cell Physiol. 2019;234(2):1671-81.

114. Deng J, Zhang N, Wang Y, Yang C, Wang Y, Xin C, et al. FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction. Stem Cell Res Ther. 2020;11(1):228.

115. Li R, Wang X, Wu S, Wu Y, Chen H, Xin J, et al. Irisin ameliorates angiotensin II-induced cardiomyocyte apoptosis through autophagy. J Cell Physiol. 2019;234(10):17578-88.

116. Wu F, Li Z, Cai M, Xi Y, Xu Z, Zhang Z, et al. Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway. Free Radic Biol Med. 2020;158:171-80.

117. Askari H, Rajani SF, Poorebrahim M, Haghi-Aminjan H, Raeis-Abdollahi E, Abdollahi M. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review. Pharmacol Res. 2018;129:44-55.

118. Díaz BB, González DA, Gannar F, Pérez MCR, de León AC. Myokines, physical activity, insulin resistance and autoimmune diseases. Immunology Letters. 2018;203:1-5.

119. Inoue K, Fujie S, Hasegawa N, Horii N, Uchida M, Iemitsu K, et al. Aerobic exercise training-induced irisin secretion is associated with the reduction of arterial stiffness via nitric oxide production in adults with obesity. Appl Physiol Nutr Metab. 2020;45(7):715-22.

120. Ma Z, Xin Z, Di W, Yan X, Li X, Reiter RJ, et al. Melatonin and mitochondrial function during ischemia/reperfusion injury. Cell Mol Life Sci. 2017;74(21):3989-98.

121. Bi J, Zhang J, Ren Y, Du Z, Li T, Wang T, et al. Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin αVβ5 receptor. J Cell Mol Med. 2020;24(1):996-1009.

122. Li RL, Wu SS, Wu Y, Wang XX, Chen HY, Xin JJ, et al. Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway. J Mol Cell Cardiol. 2018;121:242-55.

123. Nazem S, Rabiee F, Ghaedi K, Babashah S, Sadeghizadeh M, Nasr-Esfahani MH. Fndc5 knockdown induced suppression of mitochondrial integrity and significantly decreased cardiac differentiation of mouse embryonic stem cells. J Cell Biochem. 2018;119(6):4528-39.

124. Zhang M, Xu Y, Jiang L. Irisin attenuates oxidized low-density lipoprotein impaired angiogenesis through AKT/mTOR/S6K1/Nrf2 pathway. J Cell Physiol. 2019;234(10):18951-62.

125. Lin C, Guo Y, Xia Y, Li C, Xu X, Qi T, et al. FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin αV/β5-AKT signaling and reduction of oxidative/nitrosative stress. J Mol Cell Cardiol. 2021;160:27-41.

126. Liu X, Mujahid H, Rong B, Lu QH, Zhang W, Li P, et al. Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy. J Cell Mol Med. 2018;22(2):808-22.

127. Yu Q, Kou W, Xu X, Zhou S, Luan P, Xu X, et al. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci (Lond). 2019;133(5):611-27.

128. Yue R, Zheng Z, Luo Y, Wang X, Lv M, Qin D, et al. NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin. Cell Death Discov. 2021;7(1):50.

129. Pan JA, Zhang H, Lin H, Gao L, Zhang HL, Zhang JF, et al. Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells. Redox Biol. 2021;46:102120.

130. Bennett DA, Du H, Clarke R, Guo Y, Yang L, Bian Z, et al. Association of Physical Activity With Risk of Major Cardiovascular Diseases in Chinese Men and Women. JAMA Cardiol. 2017;2(12):1349-58.

131. Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O, Zugaza JL, et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat Rev Cardiol. 2018;15(12):731-43.

132. Khalafi M, Mohebbi H, Symonds ME, Karimi P, Akbari A, Tabari E, et al. The impact of moderate-intensity continuous or high-intensity interval training on adipogenesis and browning of subcutaneous adipose tissue in obese male rats. Nutrients. 2020.

133. Shirvani H, Arabzadeh E. Metabolic cross-talk between skeletal muscle and adipose tissue in high-intensity interval training vs. moderate-intensity continuous training by regulation of PGC-1α. Eating and Weight Disorders. 2020.

134. Babaei A, Nourshahi M, Fani M, Entezari Z, Jameie SB, Haghparast A. The effectiveness of continuous and interval exercise preconditioning against chronic unpredictable stress: Involvement of hippocampal PGC-1α/FNDC5/BDNF pathway. J Psychiatr Res. 2021;136:173-83.

135. Siteneski A, Olescowicz G, Pazini FL, Camargo A, Fraga DB, Brocardo PS, et al. Antidepressant-like and pro-neurogenic effects of physical exercise: the putative role of FNDC5/irisin pathway. Journal of Neural Transmission. 2020.

136. Gruhn K, Siteneski A, Camargo A, Freitas AE, Olescowicz G, Brocardo PS, et al. Physical exercise stimulates hippocampal mTORC1 and FNDC5/irisin signaling pathway in mice: Possible implication for its antidepressant effect. Behav Brain Res. 2021;400:113040.

137. Hassaan PS, Nassar SZ, Issa Y, Zahran N. Irisin vs. Treadmill Exercise in Post Myocardial Infarction Cardiac Rehabilitation in Rats. Arch Med Res. 2019;50(2):44-54.

138. Shirvani H, Rahmati-Ahmadabad S. Irisin interaction with adipose tissue secretions by exercise training and flaxseed oil supplement. Lipids Health Dis. 2019;18(1):15.

139. Amri J, Parastesh M, Sadegh M, Latifi SA, Alaee M. High-intensity interval training improved fasting blood glucose and lipid profiles in type 2 diabetic rats more than endurance training; possible involvement of irisin and betatrophin. Physiol Int. 2019;106(3):213-24.

140. Kubo H, Asai K, Kojima K, Sugitani A, Kyomoto Y, Okamoto A, et al. Exercise Ameliorates Emphysema Of Cigarette Smoke-Induced COPD In Mice Through The Exercise-Irisin-Nrf2 Axis. Int J Chron Obstruct Pulmon Dis. 2019;14:2507-16.

141. Liu Y, Guo C, Liu S, Zhang S, Mao Y, Fang L. Eight Weeks of High-Intensity Interval Static Strength Training Improves Skeletal Muscle Atrophy and Motor Function in Aged Rats via the PGC-1α/FNDC5/UCP1 Pathway. Clin Interv Aging. 2021;16:811-21.

142. Nadermann N, Volkoff H. Effects of short-term exercise on food intake and the expression of appetite-regulating factors in goldfish. Peptides. 2020;123:170182.

143. Cho E, Jeong DY, Kim JG, Lee S. The Acute Effects of Swimming Exercise on PGC-1α-FNDC5/Irisin-UCP1 Expression in Male C57BL/6J Mice. Metabolites. 2021;11(2).

144. Hegazy MA, Abdelmonsif DA, Zeitoun TM, El-Sayed NS, Samy DM. Swimming exercise versus L-carnosine supplementation for Alzheimer's dementia in rats: implication of circulating and hippocampal FNDC5/irisin. J Physiol Biochem. 2022;78(1):109-24.

145. Schaalan MF, Ramadan BK, Abd Elwahab AH. Synergistic effect of carnosine on browning of adipose tissue in exercised obese rats; a focus on circulating irisin levels. J Cell Physiol. 2018;233(6):5044-57.

146. Belviranlı M, Okudan N. Exercise training increases cardiac, hepatic and circulating levels of brain-derived neurotrophic factor and irisin in young and aged rats. Horm Mol Biol Clin Investig. 2018;36(3).

147. Uysal N, Yuksel O, Kizildag S, Yuce Z, Gumus H, Karakilic A, et al. Regular aerobic exercise correlates with reduced anxiety and incresed levels of irisin in brain and white adipose tissue. Neurosci Lett. 2018;676:92-7.

148. Tavassoli H, Heidarianpour A, Hedayati M. The effects of resistance exercise training followed by de-training on irisin and some metabolic parameters in type 2 diabetic rat model. Arch Physiol Biochem. 2019:1-8.

149. Kim HJ, Song W. Resistance training increases fibroblast growth factor-21 and irisin levels in the skeletal muscle of Zucker diabetic fatty rats. J Exerc Nutrition Biochem. 2017;21(3):50-4.

150. Zhao R, Zhou Y, Li J, Lin J, Cui W, Peng Y, et al. Irisin Regulating Skeletal Response to Endurance Exercise in Ovariectomized Mice by Promoting Akt/β-Catenin Pathway. Front Physiol. 2021;12:639066.

151. Bastu E, Zeybek U, Gurel Gurevin E, Yüksel Ozgor B, Celik F, Okumus N, et al. Effects of Irisin and Exercise on Metabolic Parameters and Reproductive Hormone Levels in High-Fat Diet-Induced Obese Female Mice. Reprod Sci. 2018;25(2):281-91.

152. Mazur-Bialy AI, Bilski J, Wojcik D, Brzozowski B, Surmiak M, Hubalewska-Mazgaj M, et al. Beneficial Effect of Voluntary Exercise on Experimental Colitis in Mice Fed a High-Fat Diet: The Role of Irisin, Adiponectin and Proinflammatory Biomarkers. Nutrients. 2017;9(4).

153. Zhu W, Sahar NE, Javaid HMA, Pak ES, Liang G, Wang Y, et al. Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. Cells. 2021;10(12).

154. Guilford BL, Parson JC, Grote CW, Vick SN, Ryals JM, Wright DE. Increased FNDC5 is associated with insulin resistance in high fat-fed mice. Physiol Rep. 2017;5(13).

155. Babaei P, Shirkouhi SG, Hosseini R, Soltani Tehrani B. Vitamin D is associated with metabotropic but not neurotrophic effects of exercise in ovariectomized rats. Diabetol Metab Syndr. 2017;9:91.

156. Yan W, Chen Y, Guo Y, Xia Y, Li C, Du Y, et al. Irisin Promotes Cardiac Homing of Intravenously Delivered MSCs and Protects against Ischemic Heart Injury. Adv Sci (Weinh). 2022;9(7):e2103697.

157. Hu C, Zhang X, Hu M, Teng T, Yuan YP, Song P, et al. Fibronectin type III domain-containing 5 improves aging-related cardiac dysfunction in mice. Aging Cell. 2022;21(3):e13556.

158. Islam MR, Valaris S, Young MF, Haley EB, Luo R, Bond SF, et al. Exercise hormone irisin is a critical regulator of cognitive function. Nat Metab. 2021;3(8):1058-70.

159. Bretland KA, Lin L, Bretland KM, Smith MA, Fleming SM, Dengler-Crish CM. Irisin treatment lowers levels of phosphorylated tau in the hippocampus of pre-symptomatic female but not male htau mice. Neuropathol Appl Neurobiol. 2021;47(7):967-78.

160. Li Q, Zhang M, Zhao Y, Dong M. Irisin Protects Against LPS-Stressed Cardiac Damage Through Inhibiting Inflammation, Apoptosis, and Pyroptosis. Shock. 2021;56(6):1009-18.

161. Ning H, Chen H, Deng J, Xiao C, Xu M, Shan L, et al. Exosomes secreted by FNDC5-BMMSCs protect myocardial infarction by anti-inflammation and macrophage polarization via NF-κB signaling pathway and Nrf2/HO-1 axis. Stem Cell Res Ther. 2021;12(1):519.